Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||
|---|---|---|---|---|---|---|
| 1801.HK | −1.67% | −9.21% | −17.56% | −7.73% | −11.83% | −3.82% |
| UCHI | −0.95% | −5.33% | −12.89% | −1.35% | −4.67% | −9.19% |
| DAOL-CHINABIO | −2.13% | −9.61% | −15.98% | −2.96% | −9.33% | −17.01% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes 1801.HK: money market or bond funds, or no holdings data yet
| UCHI | DAOL-CHINABIO | |
|---|---|---|
| Held by both | ||
 WuXi Biologics (Cayman) | 9.94% | 9.80% |
 Innovent Biologics | 8.62% | 4.88% |
| Sino Biopharmaceutical | 4.03% | 4.55% |
| Genscript Biotech Corp Class H | 3.90% | 3.22% |
| Wuxi AppTec Co Ltd Class A | 8.42% | 3.20% |
| Only in UCHI | ||
 BeOne Medicines Ltd ADR | 9.29% | N/A |
 Jiangsu Hengrui Pharmaceutic… | 5.66% | N/A |
| Akeso | 5.51% | N/A |
| Shenzhen Mindray Bio-Medical… | 2.12% | N/A |
| Only in DAOL-CHINABIO | ||
| CSPC Pharmaceutical Group | N/A | 6.71% |
| JD Health International | N/A | 6.39% |
| Alibaba Health Information T… | N/A | 3.34% |
| Shandong Weigao Group Medica… | N/A | 2.86% |
29 Jan 2026 → 3 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| 1801.HK | −3.82% | 46.84% | −0.08 |
| UCHI | −9.19% | 30.20% | −0.30 |
| DAOL-CHINABIO | −17.01% | 35.75% | −0.48 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | 1801.HK | UCHI | DAOL-CHINABIO |
|---|---|---|---|
Fund details | |||
| Fund size | N/A | 693 million | 73.32 million |
| Inception date | N/A | 25 Feb 2021 | 29 Jan 2026 |
| Master fund | N/A | กองทุนที่ลงทุนหลายกอง (Global X China Biotech, Kraneshares MSCI All China Health Care Index) | Hang Seng Biotech Index ETF |
| Dividend policy | N/A | Does not pay | Does not pay |
Risk and currency hedging | |||
| Risk level | N/A | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | N/A | 89.92% | 73.46% |
Minimum purchase and redemption | |||
| First purchase | N/A | 0.01 THB | 1 THB |
| Subsequent purchase | N/A | 0.01 THB | 1 THB |
| Redemption (amount) | N/A | 0.01 THB | No minimum |
| Redemption (units) | N/A | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | No minimum |
| Balance (units) | N/A | No minimum | 100 units |
Order cut-off and redemption payment | |||
| Buy before | N/A | 15:30 | 13:30 |
| Redeem before | N/A | 14:00 | 13:30 |
| Redemption paid | N/A | T+4 | T+3 |
